Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €89.50 EUR
Change Today -0.303 / -0.34%
Volume 473.0
As of 10:10 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

stryker corp (SYK) Snapshot

Open
€89.63
Previous Close
€89.80
Day High
€91.64
Day Low
€88.99
52 Week High
04/24/15 - €91.64
52 Week Low
04/28/14 - €54.80
Market Cap
33.9B
Average Volume 10 Days
1.4K
EPS TTM
--
Shares Outstanding
379.0M
EX-Date
03/27/15
P/E TM
--
Dividend
€1.37
Dividend Yield
1.19%
Current Stock Chart for STRYKER CORP (SYK)

stryker corp (SYK) Details

Stryker Corporation, together with its subsidiaries, operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment offers implants used in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment provides surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling and emergency medical equipment, and reprocessed and remanufactured medical devices, as well as other medical device products for use in various medical specialties. The Neurotechnology and Spine segment offers neurosurgical and neurovascular devices that include products used for minimally invasive endovascular techniques; products for traditional brain and open skull base surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also develops, manufactures, and markets spinal implant products, including cervical, thoracolumbar, and interbody systems for use in spinal injury, deformity, and degenerative therapies. The company markets its products to doctors, hospitals, and other healthcare facilities in the United States; and sells its products through company-owned sales subsidiaries and branches, as well as third-party dealers and distributors in approximately 100 countries internationally. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

26,000 Employees
Last Reported Date: 02/12/15
Founded in 1941

stryker corp (SYK) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Vice President
Total Annual Compensation: $536.7K
Group President of Medsurg & Neurotechnology
Total Annual Compensation: $568.5K
Group President of International
Total Annual Compensation: $526.7K
Group President of Orthopaedics
Total Annual Compensation: $513.3K
Compensation as of Fiscal Year 2014.

stryker corp (SYK) Key Developments

Stryker Corporation Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Second Quarter and Full Year 2015

Stryker Corporation announced unaudited consolidated sales results for the first quarter ended March 31, 2015. For the quarter, net sales were $2,379 million, operating income was $406 million, earnings before income taxes was $377 million and net earnings were $224 million or $0.58 per diluted share against net sales of $2,305 million, operating income of $131 million, earnings before income taxes of $107 million and net earnings of $70 million or $0.19 per diluted share for the same period a year ago. Net cash provided by operating activities was $380 million against $209 million a year ago. Purchases of property, plant and equipment was $46 million against $70 million a year ago. Borrowings of debt, net was $500 million. Reported net earnings include charges for the tax impacts related to the establishment of the European regional headquarters and other tax matters. Excluding the impact of the charges, adjusted net earnings of $424 million increased 5.0% in the quarter compared to the prior year. Adjusted diluted net earnings per share of $1.11 increased 4.7% in the quarter compared to the prior year. Net sales in the quarter grew by 7.1% due to increased unit volume and changes in product mix and 1.9% as a result of acquisitions. The company expects 2015 constant currency sales growth in the range of 6.0% to 7.0%, including organic sales growth in the range of 5.0% to 6.0%. Based on current foreign currency exchange rates it expects adjusted diluted net earnings per share to be in the range of $1.15 to $1.20 and $4.95 to $5.10 in the second quarter and the full year, respectively. If foreign currency exchange rates hold near current levels, it expects sales in the second quarter and full year of 2015 to be negatively impacted by approximately 3.5% to 4.5% and adjusted diluted net earnings per share to be negatively impacted by approximately $0.25 to $0.30 in the full year, approximately half of which will be in the first half of the year. The company also expect that adjusted tax rate will run at or below the level achieved in the first quarter and will be noticeably better when the benefits from the tax extenders are approved. However, capital expenditures are expected to run higher than last year as the company moves through 2015. It also repatriated approximately $700 million in the first quarter and expect to do approximately an additional $1 billion later this year.

Stryker Corp Seeks Acquisitions

Kevin Lobo, Chairman & Chief Executive Officer of Stryker Corporation (NYSE:SYK) said, "But we really look to strengthen our businesses when we're looking to do acquisitions. We want to strengthen our market position in the areas where we're playing today, and that could be big deals, small deals, or medium-size deals, but we want to make sure we're strengthening our position and encouraging our divisions to continue to drive growth. So most of the acquisitions that we pursue, and you've seen this, are catalysts for growth". Bill Jellison, Chief Financial Officer of Stryker Corporation also added, "Would we be looking or be willing to still look at an acquisition that doesn't necessarily have accretion in the first year or so? We would. It is all about whether it ultimately adds value on the back end".

Stryker Spine and Stryker Trauma and Extremities to Launch Next Generation Viable Bone Matrix at the American Academy of Orthopaedic Surgeons

Stryker Corporation's Spine and Trauma & Extremities Divisions will be launching BIO4, the next generation viable bone matrix at booth #443 during the American Academy of Orthopaedic Surgeons Annual Meeting in Las Vegas, NV from March 24-28th. From the creators of the original allograft cellular bone matrix, Osiris Therapeutics, Inc., comes the next generation, BIO4, a viable bone matrix containing endogenous bone forming cells including mesenchymal stem cells, osteoprogenitor cells, osteoblasts, osteoinductive and angiogenic growth factors. BIO4 possesses all four characteristics involved in bone repair and regeneration: osteoconductive, osteoinductive, osteogenic and angiogenic. It is a safe alternative to bone autograft that minimizes the potential for harvest site co-morbidities. With the introduction of BIO4, Stryker now plays in the growing $199 million Cellular Allograft Market.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SYK:GR €89.50 EUR -0.303

SYK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $71.14 USD -0.37
Becton Dickinson and Co $144.33 USD -0.02
Boston Scientific Corp $18.34 USD -0.08
Ecolab Inc $115.59 USD -0.26
Kimberly-Clark Corp $111.64 USD -0.06
View Industry Companies
 

Industry Analysis

SYK

Industry Average

Valuation SYK Industry Range
Price/Earnings 55.5x
Price/Sales 3.8x
Price/Book 4.4x
Price/Cash Flow 42.7x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STRYKER CORP, please visit www.strykercorp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.